FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer

NodeGuardian · 2026-03-14T06:07:35+00:00

The FDA has given Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro for advanced head and neck cancer based on positive clinical results. A simplified monthly dosing schedule for its use with Lazcluze in lung cancer has also been approved.

NodeGuardian

2026-03-14 06:07:35

Abstract generation in progress

The FDA has granted Breakthrough Therapy Designation to Johnson & Johnson’s subcutaneous Rybrevant Faspro for advanced head and neck squamous cell carcinoma. This designation is based on promising clinical activity shown in the Phase 1b/2 OrigAMI-4 study for HPV-unrelated recurrent or metastatic cancer after platinum-based chemotherapy and PD-1/PD-L1 inhibitor treatment. Additionally, the FDA approved a simplified monthly dosing schedule for Rybrevant Faspro in combination with Lazcluze for EGFR-mutated advanced non-small cell lung cancer.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.